BCM
VIRX

Burrage Capital Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Burrage Capital Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-19,502
Closed -$280K – 32
2020
Q1 		$280K Buy
19,502
+3,838
+25% +$83.3K 0.28% 30
2019
Q4 		$185K Buy
+15,664
New +$262K 0.12% 27

Other funds holding VIRX

ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Burrage Capital Management's VIRX Position: Q2 2020 in Review

Burrage Capital Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2020, closing a stake of 19,502 shares — an estimated $280K sold.

Burrage Capital Management first reported a position in VIRX in Q4 2019 and held it in 2 quarters. The position peaked at $280K in Q1 2020. 41 funds tracked by Wall St. Rank hold VIRX as of Q2 2020.

  • Burrage Capital Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Burrage Capital Management sold 19,502 Viracta Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $280K.
  • Burrage Capital Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2019 and held it in 2 quarters.
  • Burrage Capital Management's Viracta Therapeutics, Inc. Common Stock position peaked at $280K in Q1 2020.
  • 41 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Burrage Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.